+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nanomedicine in Cancer Immunotherapy

  • Book

  • January 2024
  • Elsevier Science and Technology
  • ID: 5850353

Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.

This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1. Immunoadjuvants for cancer immunotherapy
2. Nanotechnology as an emerging option in cancer immunotherapy
3. Different administration routes for nanovectors in cancer immunotherapy
4. Two-dimensional materialbased nanomedicines for cancer immunotherapy
5. Hydrogel-based nanomedicines for cancer immunotherapy
6. Exosomes-based nanomedicines for cancer immunotherapy
7. Lipid-based nanomedicines for cancer immunotherapy
8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy
9. Liposome-based nanomedicines for cancer immunotherapy
10. Biomembrane-based nanoparticles for cancer immunotherapy
11. Dendrimer-based nanomedicines for cancer immunotherapy
12. Magnetic nanocarriers for cancer immunotherapy
13. Inhaled delivery of immunotherapy for treatment of lung cancer
14. Nano-based vaccination and their administration routes in cancer immunotherapy
15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy

Authors

Prashant Kesharwani Assistant Professor, Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.

Dr. Prashant Kesharwani is working as an assistant professor of pharmaceutics at the School of Pharmaceutical Education and Research, Jamia Hamdard University, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 20 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also a receipt of several internationally acclaimed awards such as the most prestigious "Ramanujan Fellowship Award� from the Science and Engineering Research Board, Government of India. He actively participates in outreach and scientific dissemination for the service of the wider community.